Safety & Side Effects
CagriSema's side-effect profile looks a lot like the GLP-1 class it builds on: gastrointestinal events dominate and…
Mostly the gut, with class warnings to watch
CagriSema's side-effect profile looks a lot like the GLP-1 class it builds on: gastrointestinal events dominate and are dose-dependent, though the trials report low rates of stopping because of them. Layered on top are the class warnings (pancreatitis, gallbladder, thyroid) and a few theoretical amylin-specific concerns.
This unit separates the common-and-manageable from the serious-but-rare from the theoretical, and is honest that the long-term safety record simply does not exist yet.
Key terms
The gut side effects
The most common CagriSema side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In REDEFINE 1 they affected 79.6% of the CagriSema group against 39.9% on placebo, and were mainly transient and mild to moderate in severity. The sponsor release breaks the same trial down by symptom: nausea in 55% against 12.6% on placebo, constipation in 30.7% against 11.6%, and vomiting in 26.1% against 4.1%. This profile is qualitatively the same as GLP-1 drugs, made more prominent because both arms slow the stomach: the semaglutide label states that semaglutide delays gastric emptying, and amylin limits the rate of gastric emptying too.
Read that scale as illustrative. What the trials report is that the gastrointestinal events were mainly transient and mild to moderate in REDEFINE 1 and diminished over time in REDEFINE 4; no fetched source publishes a week-by-week nausea curve or names a peak week. The 16-week mark is the escalation length the REDEFINE 1 registry record gives, not a reported symptom timepoint.
The reassuring part is that these effects are mainly transient and mild to moderate, and the discontinuation figures are lower than the raw event rates suggest: the sponsor reports that stopping because of an adverse event ran to 5.9% on CagriSema against 3.5% on placebo in REDEFINE 1, and 8.4% against 3% in REDEFINE 2. In the phase 2 monotherapy trial, discontinuation attributable to gastrointestinal disorders specifically was low and not dose-dependent, occurring in two participants on 1.2 mg and one on 2.4 mg. Be careful with the frequently quoted 10.3% discontinuation figure from that trial: it is all-cause and all-arm, including liraglutide and placebo, not a gastrointestinal number.
AdvancedWhy adding amylin can add GI burden
Both arms slow gastric emptying: the semaglutide label states semaglutide delays it, and amylin limits its rate. Combining them is expected to intensify the fullness-and-nausea effect that already limits GLP-1 tolerability, which is the flip side of the additive-benefit story. The empirical half is firmer than the mechanistic one: the gastrointestinal event rate in REDEFINE 1 (79.6%) sits well above the rate seen with cagrilintide alone in the phase 2 trial (40.6% to 63.4% across doses).